These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
327 related items for PubMed ID: 27533046
1. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ. PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004926. PubMed ID: 27533046 [Abstract] [Full Text] [Related]
7. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. Kirkpatrick BD, Tenney KM, Larsson CJ, O'Neill JP, Ventrone C, Bentley M, Upton A, Hindle Z, Fidler C, Kutzko D, Holdridge R, Lapointe C, Hamlet S, Chatfield SN. J Infect Dis; 2005 Aug 01; 192(3):360-6. PubMed ID: 15995948 [Abstract] [Full Text] [Related]
8. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Kirkpatrick BD, McKenzie R, O'Neill JP, Larsson CJ, Bourgeois AL, Shimko J, Bentley M, Makin J, Chatfield S, Hindle Z, Fidler C, Robinson BE, Ventrone CH, Bansal N, Carpenter CM, Kutzko D, Hamlet S, LaPointe C, Taylor DN. Vaccine; 2006 Jan 12; 24(2):116-23. PubMed ID: 16140433 [Abstract] [Full Text] [Related]
9. Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi. Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y. Front Cell Infect Microbiol; 2017 Jan 12; 7():135. PubMed ID: 28484685 [Abstract] [Full Text] [Related]
11. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. Cartee RT, Thanawastien A, Griffin Iv TJ, Mekalanos JJ, Bart S, Killeen KP. PLoS Negl Trop Dis; 2020 Jan 12; 14(1):e0007912. PubMed ID: 31905228 [Abstract] [Full Text] [Related]
12. Live oral typhoid vaccine Salmonella Typhi Ty21a - a surrogate vaccine against non-typhoid salmonella? Kantele A, Pakkanen SH, Siitonen A, Karttunen R, Kantele JM. Vaccine; 2012 Nov 26; 30(50):7238-45. PubMed ID: 23084770 [Abstract] [Full Text] [Related]
15. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC. N Engl J Med; 2001 Apr 26; 344(17):1263-9. PubMed ID: 11320385 [Abstract] [Full Text] [Related]
19. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans. Wahid R, Pasetti MF, Maciel M, Simon JK, Tacket CO, Levine MM, Sztein MB. Clin Immunol; 2011 Feb 26; 138(2):187-200. PubMed ID: 21146460 [Abstract] [Full Text] [Related]